Ovid Therapeutics (OVID) Cash from Operations (2016 - 2026)

Ovid Therapeutics has reported Cash from Operations for 11 years, with the latest figure at 13899000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 35.2% year-over-year to 13899000.0; the trailing twelve-month figure through Mar 2026 stood at 41919000.0 (up 15.4% YoY), and the FY2025 full-year result was 38300000.0, up 31.55% from the prior year.
• Cash from Operations for Q1 2026 stood at 13899000.0, down from 10374000.0 in the prior quarter.
• The five-year high for Cash from Operations was 4774000.0 in Q2 2025, with the low at 20086419.0 in Q1 2022.
• Historically, Cash from Operations has averaged 12303713.35 across 5 years, with a median of 12112000.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Operations plunged 112.48% — and 2025, when it soared 66.51%.
• Ovid Therapeutics' Cash from Operations stood at 9175732.0 in 2022, then retreated by 29.81% to 11911000.0 in 2023, then gained by 15.98% to 10008000.0 in 2024, then dropped by 3.66% to 10374000.0 in 2025, then tumbled by 33.98% to 13899000.0 in 2026.
• The last three Cash from Operations figures came in at 13899000.0 (Q1 2026), 10374000.0 (Q4 2025), and 12872000.0 (Q3 2025), per Business Quant data.